Overview

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are: 1. To evaluate the effect of ABT-335 (choline fenofibrate) on several parameters of RCT (reverse cholesterol transport) in men and post-menopausal women diagnosed with dyslipidemia (i.e., low high-density lipoprotein [HDL] cholesterol levels and elevated triglyceride [TG] concentrations). 2. To evaluate longitudinal changes in several parameters of RCT in subjects with low HDL. 3. To obtain pilot data for power calculations for subsequent comparative study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Radiant Research
Treatments:
Choline
Fenofibrate